Darolutamide receives approval for additional prostate cancer indication in Japan
27 February 2023 at 9:00 EET
Darolutamide receives approval for additional prostate cancer indication in Japan
- Darolutamide approved for metastatic prostate cancer as well as non-metastatic castration-resistant prostate cancer
- New approval is based on data from the pivotal Phase III ARASENS trial
The Ministry of Health, Labor and Welfare (MHLW) in Japan has approved the oral androgen receptor inhibitor (ARi) darolutamide plus ADT in combination with docetaxel in the indication of metastatic prostate cancer. The MHLW approval is based on the positive results from the Phase III ARASENS trial, which demonstrated that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel significantly reduced the risk of death by 32.5% compared to ADT with docetaxel, in patients with metastatic hormone-sensitive prostate cancer (mHSPC). Additionally, the darolutamide combination showed consistent benefits across clinically relevant secondary endpoints, with the overall incidence of treatment-emergent adverse events being similar between treatment arms. These results were published in The New England Journal of Medicine.1
Darolutamide is already approved in Japan for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) under the brand name Nubeqa®.
Darolutamide plus ADT in combination with docetaxel was recently recommended for EU marketing authorisation for the treatment of mHSPC by the European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP), with a final decision expected in the coming months. The compound is already approved in its second indication, mHSPC, in a number of markets including the U.S. Filings in other regions are underway or planned by Orion’s collaboration partner Bayer.
Darolutamide is being investigated in a broad development program with three additional ongoing or planned large clinical studies, to evauate its potential across prostate cancer patients from the early- to the late-stage of this disease. This includes the ARANOTE Phase III trial evaluating darolutamide plus androgen deprivation therapy (ADT) versus ADT alone for mHSPC.
Darolutamide is developed jointly by Orion and Bayer.
About the ARASENS Trial
The ARASENS trial is a randomized, Phase III, multi-center, double-blind, placebo-controlled trial which was prospectively designed to investigate the efficacy and safety of oral darolutamide, an androgen receptor inhibitor (ARi), plus androgen deprivation therapy (ADT) and the chemotherapy docetaxel in patients with metastatic hormone-sensitive prostate cancer (mHSPC). A total of 1,306 newly diagnosed patients were randomized in a 1:1 ratio to receive 600 mg of darolutamide twice a day or matching placebo, plus ADT and docetaxel.
The primary endpoint of this trial was overall survival (OS). Secondary endpoints included time to castration-resistant prostate cancer (CRPC), time to pain progression, time to first symptomatic skeletal event (SSE), time to initiation of subsequent anticancer therapy, all measured at 12‐week intervals, as well as adverse events (AEs) as a measure of safety and tolerability. Results from this trial were published in the New England Journal of Medicine.1 A plain language summary publication of these data was published in Future Oncology.2 The ARASENS trial demonstrated that darolutamide plus androgen deprivation therapy (ADT) and docetaxel significantly reduced the risk of death by 32.5% compared to ADT plus docetaxel.1 Improvements in the secondary endpoints supported the benefit observed in the primary endpoint, overall survival.1
About Metastatic Hormone-Sensitive Prostate Cancer
Prostate cancer is the second most commonly diagnosed malignancy in men worldwide. In 2020, an estimated 1.4 million men were diagnosed with prostate cancer, and about 375,000 died from the disease worldwide.3
At the time of diagnosis, most men have localized prostate cancer, meaning their cancer is confined to the prostate gland and can be treated with curative surgery or radiotherapy. Upon relapse, when the disease will metastasise or spread, or if the disease is newly diagnosed, but has already spread, the disease is hormone-sensitive and androgen deprivation therapy (ADT) is the cornerstone of treatment for this hormone-sensitive disease. Current treatment options for men with metastatic hormone-sensitive prostate cancer (mHSPC) include hormone therapy, such as ADT, androgen receptor pathway inhibitors plus ADT or a combination of docetaxel chemotherapy and ADT. Despite these treatments, a large proportion of men with mHSPC will eventually experience progression to metastatic castration-resistant prostate cancer (mCRPC), a condition with limited survival.
Darolutamide is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, thereby inhibiting the receptor function and the growth of prostate cancer cells. The low potential for blood-brain barrier penetration for darolutamide is supported by preclinical models and neuroimaging data in healthy humans. This is supported by the overall low incidence of central nervous system (CNS)-related adverse events (AEs) compared to placebo as seen in the ARAMIS Phase III trial4 and the maintained verbal learning and memory observed in the darolutamide arm of the Phase II ODENZA trial.5
The product is approved under the brand name Nubeqa® in more than 80 countries around the world, including the U.S., EU, Japan and China, for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease. It is also approved for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) in a number of markets including the U.S. Filings in other regions are underway or planned by Bayer. The compound is also being investigated in further studies across various stages of prostate cancer, including in the ARANOTE Phase III trial evaluating darolutamide plus androgen deprivation therapy (ADT) versus ADT alone for metastatic hormone-sensitive prostate cancer (mHSPC), as well as the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) led international Phase III co-operative group DASL-HiCaP (ANZUP1801) trial evaluating darolutamide as an adjuvant treatment for localised prostate cancer with very high risk of recurrence. Information about these trials can be found at www.clinicaltrials.gov. In addition, a study to explore the potential of darolutamide in the early setting for patients who have experienced a rise in their prostate specific antigen (PSA) levels following surgery or radiation, is also planned.
Tuukka Hirvonen, Investor Relations
tel. +358 10 426 2721
- Smith MR, Hussain M, Saad F, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 386:1132-1142 (2022).
- Smith M., Hussain M., Saad F. et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial. Future Oncol. 2022;18:21:2585-2597. https://doi.org/10.2217/fon-2022-0433.
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.3322/caac.21660. Accessed January 2023.
- Fizazi, K et al. N Engl J Med. 2019; 380:1235–1246.
- Colomba E. et al. J Clin Onc 2021; 39 (15_suppl): 5046-5046.
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Forløb af ordinær generalforsamling 2023, 2. meddelelse21.3.2023 15:14:40 CET | pressemeddelelse
Forløb af ordinær generalforsamling 2023, 2. meddelelse Vedhæftet fil Forløb af ordinær generalforsamling 2023, meddelelse 2
Flagning af generalforsamlingsfuldmagter til bestyrelsen21.3.2023 15:11:18 CET | pressemeddelelse
Til Nasdaq OMX Copenhagen 21. marts 2023 Selskabsmeddelelse nr. 03/2023 Flagning af generalforsamlingsfuldmagter til bestyrelsen I henhold til bekendtgørelse nr. 1172 af 31. oktober 2017 om storaktionærer meddeles det, at der til brug for GrønlandsBANKENs generalforsamling den 28. marts 2023 har GrønlandsBANKENs bestyrelse modtaget blankostemmefuldmagter, som repræsenterer 31,38 procent af aktiekapitalens stemmerettigheder eller 564.804 stk. aktier Den 28. marts 2023, når den ordinære generalforsamling er afholdt, ophører bestyrelsens adgang til at stemme i henhold til de modtagne fuldmagter. Eventuelle henvendelser kan rettes til: GrønlandsBANKEN Martin Kviesgaard Bankdirektør Direkte telefon: +299 34 78 02 firstname.lastname@example.org Vedhæftet fil 03.Flagning_blankofuldmagter
Announcement of the granting of Power of Attorney to the Board of Directors21.3.2023 15:11:18 CET | Press release
To Nasdaq OMX Copenhagen 21 March 2023 Company Announcement No 03/2023 Announcement of the granting of Power of Attorney to the Board of Directors Pursuant to announcement no 1172 of 31 October 2017 regarding Major Shareholders, The BANK of Greenland hereby announces, that the Board of Directors have received unqualified Powers of Attorney for use on The BANK of Greenland’s ordinary general meeting March 28, 2023, representing 31.38 percent of the company’s share capital, or 564,804 shares. 28 March 2023 upon termination of the ordinary general meeting, the right of the Board of Director’s to vote in accordance with the Powers of Attorney granted shall cease. For further information, please contact: The BANK of Greenland Martin Kviesgaard Managing Director Telephone: +299 34 78 02 E-mail: email@example.com Attachment 03.Flying of flags_unqualified powers of attorney
New member proposed for election to the Board of Directors21.3.2023 14:38:36 CET | Press release
Company announcement no 6-2023 Copenhagen, March 21, 2023 New member proposed for election to the Board of Directors Konsolidator’s Board of Directors proposes that Peter Gath is elected as a new member of the Board of Directors at the company’s upcoming Annual General Meeting scheduled for 23 March 2023. Consequently, Konsolidator’s Board of Directors proposes that the company’s Board of Directors will consist of five members: the Chairman of the Board, Jesper Eigen Møller, and the members Thomas Aporta, Cecilia Hultén, Claus Jul Christiansen, and Peter Gath. Peter Gath enters the Board of Directors with over 20 years of experience as a partner from EY and KPMG. Peter is currently CFO of St. Jørgen Holding and holds multiple Board Member positions, incl. in the listed company Brødrene A & O Johansen A/S. As a Chartered Accountant with a background in audit and leadership, as well as an Adjunct Professor at Copenhagen Business School (CBS) and former Chairman of the Danish Institute of
SELIGSON & CO OMX HELSINKI 25 EXCHANGE TRADED FUND UCITS ETF: ANNUAL REPORT, BOARD OF THE MANAGEMENT COMPANY AND AUDITOR21.3.2023 14:30:00 CET | Press release
Seligson & Co Fund Management Company Plc STOCK EXCHANGE NOTICE 21 March 2023 SELIGSON & CO OMX HELSINKI 25 EXCHANGE TRADED FUND UCITS ETF: ANNUAL REPORT, BOARD OF THE MANAGEMENT COMPANY AND AUDITOR The Annual Report of Seligson & Co OMX Helsinki 25 Exchange Traded Fund UCITS ETF, dated 31 December 2022, has been published. The report, which is in Finnish, forms part (pages 41 to 47) of the attached common Annual Report for the Seligson & Co funds. The report and the Auditor's Report are also available at www.seligson.fi/sco/suomi/esitteet/. The following members were elected to the board of Seligson & Co Fund Management Company Plc at the Annual General Meeting held on 21 March 2023: Samu Anttila, Jarkko Niemi and Mikko Vasko. KPMG Plc was chosen as the auditor and CPA Marcus Tötterman as the deputy auditor. Further information: Mari Rautanen email: firstname.lastname@example.org Phone +358 (0)9 6817 8224 Seligson & Co Fund Management Company Plc Ari Kaaro Managing Director email: ari.kaar